What happened Shares of Paratek Pharmaceuticals (NASDAQ: PRTK) flew nearly 20% higher on Tuesday, on an otherwise forgettable day for the stock market. There was little mystery why -- the company won another approval for its next-generation antibiotic Nuzyra.
Full Answer
Where can I buy shares of prtk?
Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Can Paratek (prtk) beat earnings expectations?
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What does prtku stand for?
PRTKU.S.: Nasdaq Paratek Pharmaceuticals Inc. WatchlistCreatePRTKAlert PRTKUS After Hours Last Updated: Jan 19, 2022 4:49 p.m. ESTDelayed quote $4.2500 0.000.00% After Hours Volume:3.78K
What is the price of Paratek Pharmaceuticals Inc (prtkus)?
Paratek Pharmaceuticals Inc. WatchlistCreatePRTKAlert PRTKUS After Hours Last Updated: Jan 19, 2022 4:49 p.m. ESTDelayed quote $4.2500 0.000.00% After Hours Volume:3.78K Close Chg Chg % $4.2500 -0.0600 -1.39% Toggle Chart Options Advanced Charting
See more
Is PRTK a good stock to buy?
The financial health and growth prospects of PRTK, demonstrate its potential to perform inline with the market. It currently has a Growth Score of A. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Why is PRTK stock dropping?
Shares of Paratek Pharmaceuticals (PRTK 4.47%) were sinking 10.9% as of 11:46 a.m. EDT on Wednesday. The big decline came after the company announced that it's lowering its 2021 revenue outlook by around $38 million following discussions with the Biomedical Advanced Research and Development Authority (BARDA).
Is paratek a good company?
100% of employees would recommend working at Paratek Pharmaceuticals with the overall rating of 3.8 out of 5. Employees also rated Paratek Pharmaceuticals 2.1 out of 5 for Company Culture, 3.0 for Rewards You Receive, 4.1 for Growth Opportunities and 3.8 for support you get.
Who owns paratek pharmaceuticals?
AIGH CAPITAL MANAGEMENT LLC Bought 800.6 Thousand shares of Paratek Pharmaceuticals I...
How many employees does paratek have?
Company Growth (employees)Employees (est.) (Feb 2019)101(+24%)Job Openings1Website Visits (Feb 2022)7 kRevenue (FY, 2020)$46.9 M(+184%)Share Price (May 2022)$1.9(+2%)1 more row
Does Omadacycline cover Pseudomonas?
Like other tetracyclines, omadacycline displays no notable activity against Proteus spp. (MIC90 ≥32 μg/mL), Providencia spp. (MIC90 >16 μg/mL), Morganella spp. (MIC90 >16 μg/mL), or Pseudomonas spp.
Is PRTK stock a buy right now?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 1 buy rating...
Will Paratek Pharmaceuticals' stock price go up in 2022?
2 Wall Street research analysts have issued 1-year price objectives for Paratek Pharmaceuticals' stock. Their forecasts range from $11.00 to $30.00...
How has Paratek Pharmaceuticals' stock performed in 2022?
Paratek Pharmaceuticals' stock was trading at $4.49 at the beginning of 2022. Since then, PRTK stock has decreased by 47.2% and is now trading at $...
When is Paratek Pharmaceuticals' next earnings date?
Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast fo...
How were Paratek Pharmaceuticals' earnings last quarter?
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings results on Wednesday, May, 4th. The specialty pharmaceutical company repo...
What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?
Paratek Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for t...
Who are Paratek Pharmaceuticals' key executives?
Paratek Pharmaceuticals' management team includes the following people: Mr. Michael F. Bigham CPA , CPA, M.B.A., MBA, Exec. Chairman (Age 64, Pa...
Who are some of Paratek Pharmaceuticals' key competitors?
Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ) , Pfizer (PFE) , Eli Lilly and (LLY) , AbbVie (ABBV)...
What other stocks do shareholders of Paratek Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento The...
Which PRTK drug has been included?
The goal of Paratek is to develop and commercialize novel therapeutics for the treatment of life-threatening diseases and other health threats, for civilian, national and military audiences.
How PRTK Stock went through it?
In order to assist in the development of comprehensive recommendations, the CDC conducted systematic literature reviews on the treatment of plague in humans and other relevant topics and has recommended PRTK’s drug as an alternative. Paratek (PRTK) conducted a research study of NUZYRA against pathogenic agents, including Y.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry.
Headlines
Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ...
Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock.
What is the NDA for Paratek Nuzyra?
Paratek announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (NDA) for the oral-only formulation of Nuzyra to treat adults suffering from community-acquired bacterial pneumonia (CABP), a lung disease.
Is Paratek a big mover?
Paratek (PRTK) was a big mover last session on higher -than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
When will Paratek Pharmaceuticals be available for stock?
(Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on May 28, 2021, the Company granted stock options to six new employees of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2
What is the NDA for Paratek Nuzyra?
Paratek announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (NDA) for the oral-only formulation of Nuzyra to treat adults suffering from community-acquired bacterial pneumonia (CABP), a lung disease.
When is Paratek webinar 2021?
(Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that it will host an investor webinar on Wednesday, June 16, 2021, at 10:00 a.m. Eastern Time. During the webinar, Paratek will provide a corporate overview and an upd